20 May 2015 07:00
20 May 2015
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Innovenn now offering microbiology & histology services from new state of the art labs
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, today announced that InnoVenn, the skin science division of Venn, has expanded its service offering with the addition of Microbiology and Histology services.
Innovenn offers clients in the cosmetic, personal care, medical device and pharmaceutical sectors tailor-made research programmes to develop skincare ingredients and products. The new services include the antimicrobial profiling of ingredients, investigation of pro and prebiotic effects on natural microflora and the quantitative microbiology of the skin. Innovenn's renowned team of experts carry out research using their leading human skin equivalent, Labskin, which allows for the direct testing of topical materials and formulations on a living skin surface.
The Company's Skin Histology laboratory provides services dedicated to cutaneous biology, including sample processing, imaging and evaluation. It is tightly integrated with the LabSkin in vitro skin model production and testing facility, enabling customers to conduct animal-free assessments of their ingredients and products for multiple parameters including irritation, penetration, UV damage, and antimicrobial activity. Innovenn has also recently expanded its workforce to deal with increasing international demand for their research and development services and the production of Labskin.
Commenting on the additional services Venn CEO, Tony Richardson stated: These new services demonstrate the capabilities of Labskin and how innovative, robust and precise the product is. We are looking forward to offering these services to our current and expanding list of international clients".
Enquiries:
Venn Life Sciences Holdings Plc | www.vennlifesciences.com |
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 |
Orla McGuinness, Marketing Manager | Tel: +33 676931178 |
Zeus Capital (Nominated Adviser and Broker) | |
Ross Andrews/Andrew Jones | Tel: 0161 831 1512 |
Alex Davies | Tel: 020 7533 7727 |
Walbrook PR Ltd | Tel: 020 7933 8787 or venn@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
About InnoVenn
InnoVenn (55.6% owned by Venn) is a market development accelerator dedicated to rapidly commercialising proven scientific breakthroughs in the form of products and technologies primarily in Skin Science. These include Labskin the breakthrough research grade human skin testing platform as well as the clinically proven Blemish Control Technology for the professional skincare market. For more information on Innovenn, visit www.innovenn.co.uk
About Venn Life Sciences Limited
Venn Life Sciences is a Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK and Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science. For more information, visit www.vennlifesciences.com.